Inside Binaytara’s National Hematology Summit: Top Abstracts
Author
Binaytara Team
Anatomy of a National Hematology Conference
Excitement is building as the hematology community heads into the final month before Binaytara’s National Summit on Hematologic Cancers. The Summit’s call for abstracts garnered a record-breaking influx of submissions, originating from 18 countries and 5 continents: North and South America, Africa, Asia, and Europe. 121 global institutions were represented across almost 700 authors, led by University of Texas MD Anderson Cancer Center, Vanderbilt University Medical Center, and H. Lee Moffitt Cancer Center and Research Institute.
Ultimately, the Summit’s abstract committee accepted 84 field-disrupting abstracts. Of these, five were given the additional distinction of acceptance for oral presentation. The Summit, which will take place on October 16 and 17 in Nashville, TN, will see these authors’ research more fully explored. For those who can’t make it, keep an eye on the International Journal of Cancer Care and Delivery, the independent, peer-reviewed medical journal supported by Binaytara: all accepted abstracts will be made available to read.
Until then, there’s no time like the present: preview the research abstracts that caught the attention of the National Summit on Hematologic Cancers’ all-star abstract faculty.
Abstracts Selected for Oral Presentation
Tumor Microenvironment-Guided Therapeutic Selection in Peripheral T-Cell Lymphoma: Non-Overlapping At-Risk Populations Targetable by Anti-TIM-3 and Anti-CCR4 Agents (Northwell Health Cancer Institute)
Authors: Pratik Shah, MD; Adit Singhal, MD; Cho Han Chiang, MD
A three-way collaboration from Northwell Health Cancer Institute contributed this biomarker study, which set out to solve a gap in treating peripheral T-cell lymphoma (PTCL). Two promising new drug classes exist, but doctors have had little way to know which patients would benefit from which one.
Using gene-expression data from 193 PTCL tumors, the authors sorted each tumor's immune-cell makeup into one of three "microenvironment" types, then traced two specific biological pathways — each linked to a different experimental therapy (anti-TIM-3 antibodies like sabatolimab and cobolimab, or the anti-CCR4 antibody mogamulizumab) — across those types. The two pathways turned out to operate independently of each other, and showed up in different tumor environments: the TIM-3 pathway clustered in one immune subtype, the CCR4 pathway in another.
Roughly two-thirds of at-risk patients had only one of the two pathways active, suggesting their tumor's dominant biology could point directly to a single targeted treatment rather than a guess. Patients with both pathways elevated fared the worst — a median survival of under a year — and the authors suggest this smaller subgroup may be the ones who'd benefit from combining both drug classes rather than choosing one. The authors note that prospective validation of this framework is still needed before it could guide treatment decisions in practice.
Pre-transplant growth differentiation factor-15 independently predicts survival following allogeneic hematopoietic cell transplantation (Roswell Park Comprehensive Cancer Center)
Authors: Rahul Thakur, MD; Nisha Nair, MPH; Chelsea Peterson, DO; Alex Niu, MD; Eshan Malek, MD; Grant Schofield, MD; Alicia Lieberman, MD; Ross Maureen, MD; Philip Mccarthy, MD; Brian Betts, MD; Marco Davila, MD; Meghan Herr, PhD; Shernan Holtan, MD
A team from Roswell Park Comprehensive Cancer Center tackled a persistent problem in stem cell transplant care: doctors still struggle to identify, ahead of time, which patients are physically vulnerable to a rough outcome. Their candidate solution is a blood marker called GDF15 — a protein the body releases under stress from tissue injury, chemotherapy, or inflammation, and one increasingly of interest since new drugs can now target it directly.
Looking back at 152 adults who underwent allogeneic stem cell transplants between 2018 and 2025, the authors measured each patient's GDF15 level before transplant and split them into three groups, from lowest to highest. The pattern was stark: patients in the highest GDF15 group had a one-year survival rate of just 51%, compared to 88% for the lowest group — and GDF15 remained an independent predictor of survival even after accounting for other known risk factors like donor type and heart disease. Higher GDF15 also tracked with a greater risk of dying from transplant-related causes and a higher rate of acute graft-versus-host disease, a common transplant complication where donor immune cells attack the recipient's body.
The authors frame this as an early but promising step: GDF15 could eventually help doctors flag high-risk patients before transplant and, since drugs targeting the GDF15 pathway already exist, potentially treat that risk directly rather than just identifying it.
Germline predisposition to immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) after CAR T cell therapy for lymphoma and myeloma (MD Anderson)
Authors: Anath Lionel, MD, PhD; Cao Cuong Le, PhD; Jianlong Liao, PhD; Federico Mario Aletti, MD; Faezeh Darbaniyan, PhD; Sushanth Gouni, MD; Xubin Li, PhD; Jared Henderson, PhD; Ajlan Al Zaki, MD, PhD; Aniruddha Mundhada, MBBS; Christen Dillard, MD; Sherif Seif, MD; David Berrios Nolasco, MSc; Amy Ayers, MSc; Misha Hawkins, MSN; Fateeha Furqan, MBBS; Ayushi Chauhan, MBBS; Hun Ju Lee, MD; Luis Fayad, MD; Ranjit Nair, MD; Luis Malpica, MD; Chijioke Nze, MD; Preetesh Jain, MD, PhD; Michael Wang, MD; Elizabeth Shpall, MD; Partow Kebriaei, MD; Dai Chihara, MD, PhD; Paolo Strati, MD; Jason Westin, MD; Christopher Flowers, MD, PhD; Sheeba Thomas, MD; Michelle Hildebrandt, PhD; Sairah Ahmed, MD; Swaminathan Iyer, MD; Mark Hamilton, MD, PhD; Krina Patel, MD; Linghua Wang, PhD; Michael Green, PhD; Sattva Neelapu, MD
A 38-author team from MD Anderson dug into the genetics behind IEC-HS, a rare but potentially fatal inflammatory complication of CAR T-cell therapy. The condition looks a lot like a known inherited immune disorder, so the authors sequenced the DNA of 18 patients who developed it and compared them to 59 who didn't.
Patients with IEC-HS carried far more damaging mutations in genes tied to that inherited disorder — and lab experiments confirmed a mechanism: CAR T-cells engineered with those same gene defects were less effective at killing tumor cells but produced a flood of inflammatory signals instead.
The authors suggest these inherited variants may help identify, before treatment even begins, which patients are at higher risk for this dangerous side effect.
A Hematopoietic Stem Cell Transplantation AI Foundation Model for Individualized Prediction of Relapse and Non-relapse Mortality (The Ohio State University, Tampa General Hospital Cancer Institute, Thomas Jefferson University)
Authors: Jiasheng Wang, MD; David Swoboda, MD; Aziz Nazha, MD
A three-institution team built HCTab-FM, an AI model trained specifically to predict two of the biggest risks after a stem cell transplant: cancer relapse and death from transplant complications unrelated to relapse. The model draws on nearly 470,000 patient records pooled from 88 public transplant registries — a scale that's historically been hard to use because each registry tracks different variables.
The authors also built a pipeline letting doctors describe a patient's case in plain language, which the system automatically translates into the structured data the model needs. Tested against a real hospital's patient records, HCTab-FM outperformed several standard prediction methods, and its predicted risk estimates for a set of test scenarios lined up reasonably well with what actually happened to those patients.
The authors frame this as a scalable way to build more personalized risk predictions for transplant patients going forward.
Somatic mitochondrial DNA mutations with high heteroplasmy mark rapidly expanding clonal hematopoiesis
Hidetaka Uryu, MD, PhD; Satoko Ogata, PhD; Koichi Saeki, PhD; Zheng You, PhD; Zongrui Li, MSc; Sarah Hanache, PhD; Nehali Shah, MSc; Robert Orlowski, MD, PhD; Muzaffar Qazilbash, MD; Courtney DiNardo, MD, MSc; Simona Colla, PhD; Rashmi Kanagal-Shamanna, MD; Carlos Bueso-Ramos, MD, PhD; Gheath Al-Atrash, MD, PhD; Jeffrey Molldrem, MD; Andrew Futreal, PhD; Elizabeth Shpall, MD; Guillermo Garcia-Manero, MD; Margaret Goodell, PhD; Hiroshi Haeno, PhD; Koichi Takahashi, MD, PhD
This international collaboration tackled a longstanding puzzle in clonal hematopoiesis (CH) — a common, age-related condition where a single blood stem cell's descendants start to outgrow the rest, sometimes as a precursor to blood cancer. The problem: doctors have no reliable way to tell which of these expanding clones are dangerous.
The authors found a candidate answer in an unexpected place — mitochondrial DNA. By tracing genetic mutations across more than 1,200 blood stem cell colonies from myeloma patients and healthy donors, they found that the fastest-expanding, highest-risk clones tended to carry their own distinct, near-total mitochondrial mutations, regardless of which cancer-associated gene was driving the clone. In patients who were followed over time, the clones that went on to develop into leukemia or MDS (a related blood disorder) showed this mitochondrial signature especially strongly beforehand — though the signal faded once the cells fully transformed into cancer, suggesting the mitochondrial mutations may matter most in the earlier, higher-risk expansion phase rather than after cancer has already taken hold.
The authors propose this mitochondrial marker as a potential new way to flag which CH cases carry the highest risk of progressing to blood cancer.
Full abstract text available soon.
A National Conversation, Built on Global Contributions
Five oral presentations, five very different angles on the same broader challenge: giving clinicians better tools to see risk coming before it arrives, whether that risk shows up in a strand of mitochondrial DNA, a blood marker drawn before transplant, or a gene variant inherited long before a diagnosis. Taken together with the full slate of 84 accepted abstracts, this year's Summit reflects a field increasingly defined by precision, prediction, and collaboration across institutional and international lines.
That collaborative reach isn't incidental. With submissions spanning 18 countries and 5 continents, the Summit continues to serve as a place where hematology's biggest questions get worked out in the open, across borders and institutions. Join the authors above, along with faculty from across the country, at Binaytara's National Summit on Hematologic Cancers, October 16–17 in Nashville, TN.
